RxDoctor Payments Data

Michael Zavaski, MD

Urology · Springfield, MANPI 1427491919

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $20,969 of the $22,781 with a category attached, or 92.0%. Boston Scientific accounts for 95.3% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $10,474 and has fallen 96.1% since, to $413 in 2025.

$22,781in general payments, 2019–2025

Across 65 payments — averaging $350.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$22K
  • Ferring Pharmaceuticals Inc.$205
  • Sumitomo Pharma America, Inc.$192
  • Urogen Pharma, Inc.$162
  • Accord Healthcare, Inc.$119
  • Olympus America Inc.$108
  • plus $290 from 9 others

What the payments were for

  • Consulting fees$20,96992%
  • Travel & lodging$6683%
  • Food & beverage$1,1445%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,781 in reported general payments places this provider in the 85th percentile of 327 urology providers in Massachusetts.

See all urology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$865,616
Medicare patients
2,161
Services billed
15,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron163$138,706
MyrbetriqMirabegron132$90,491
Tamsulosin Hcl677$12,289
Finasteride413$8,093
Testosterone25$3,748
Potassium Citrate ErPotassium Citrate30$3,595
Methenamine Hippurate39$3,093
Estradiol30$1,677
Trospium Chloride22$1,229
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst50$1,028
Alfuzosin Hcl ErAlfuzosin Hcl32$1,015
Oxybutynin Chloride ErOxybutynin Chloride20$730
Dutasteride22$561
Tadalafil21$518
Terazosin Hcl20$480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$192$138,706163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 327 urology providers in Massachusetts.

Other urology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →